Natera Inc NTRA

$NTRA +CYDY = $$$$$!!!!

https://www.cnbc.com/video/2026/11/12/final-trades-micron-digital-realty-natera-and-moodys.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtensio $MU $DLR $MCO $NTRA

$NTRA the $9.5 million natera billing settlement is open, claim by may 3, 2027, per open class actions. suit alleges patients were billed over the promised threshold. seems like billing bills come due

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: $PRPO ) reported record quarterly revenue of $7.3M for the third quarter ended September 30, 2026, up 8% year-over-year from $6.8M in Q3-2025. Precipio also reported positive Adjusted EBITDA, a non-GAAP measure, and strong operating cash flow, with additional results in its Form 10-Q filed on November 10, 2026. Precipio, Inc. is a B2i Digital Featured Company. See the company's in-depth profile at: https://b2idigital.com/precipio-inc Both revenue lines grew year-over-year, Adjusted EBITDA stayed positive, and the quarter closed with a larger cash balance than a year earlier: • Product revenue was $1.0M, up 40% year-over-year from $0.7M in Q3-2025 • Pathology revenue was $6.3M, up 5% year-over-year from $6.0M in Q3-2025 • Adjusted EBITDA, a non-GAAP measure, was a positive $0.4M • Cash flow from operations was $0.6M, and total cash increased by $0.5M, resulting in an end-of-quarter cash balance exceeding $3.5M, vs $2.3M in Q3-2025 Ilan Danieli, Chief Executive Officer of Precipio, commented on the company's third-quarter performance in the announcement. “In the third quarter we continued to strengthen our financial position, delivering record revenue while maintaining positive Adjusted EBITDA and generating cash from operations,” said Danieli. Read the full release: https://www.precipiodx.com/precipio-announces-q3-2026-financial-results/ Precipio is a healthcare biotechnology company focused on cancer diagnostics. Its mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services that deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in its laboratory where it designs, tests, validates, and uses these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scale Precipio’s reach to eradicate misdiagnosis. More information is available at https://www.precipiodx.com. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://b2idigital.com/disclaimer. $EXAS, $NTRA, $GH, $XBI

$NTRA $TEM

$TEM There is so much hidden value in $TEM that is currently underappreciated, but will eventually generate billions in annual revenue. Take a close look at their apps business and ask yourself what it will look like once all of their AI enabled apps are reimbursed. This is already starting to happen since the health economic benefits of those applications are becoming obvious. Then there is the cancer vaccine business which will bring substantial revenue. Also the MRD business will scale faster and be larger than most realize - rivaling $NTRA. Once CRC gets a positive MolDx approval MRD revenue will explode higher. Lastly, I do expect the large frontier labs to become their largest data customers in the near future. Tempus will have diverse revenue streams which will compound for many years.

$NTRA https://webinarsreg.endpoints.news/is-your-drug-working-earlier-insights-with-molecular-response-monitoring-and-rwd/?utm_source=natera&utm_campaign=4518218419&utm_medium=collateral